I
n the human population, two to eight C4 genes may be present in a diploid genome. In other words, the number of C4 genes present in the class III region of the MHC on each copy of the chromosome 6 varies between one and four among different individuals (1, 2) . Duplication, triplication, and quadruplication of C4 genes are always concurrent with the neighboring genes RP at the 5Ј region and CYP21 and TNX at the 3Ј region (3) (4) (5) . This discrete duplication unit is known as an RCCX 3 module. In Caucasians, more than two-thirds of the MHC haplotypes have two C4 genes; the other haplotypes mainly possess either a single C4 gene or triple C4 genes. Each of these C4 genes may be long (L) or short (S), depending on the presence or absence of the 6.34-kb human endogenous retrovirus HERV-K(C4) in intron 9 (6, 7) . Each of the C4 genes code for either an acidic (C4A) or a basic (C4B) protein. The C4A and C4B isotypes are mainly defined by four specific amino acid residues at positions 1101, 1102, 1105, and 1106, which are encoded by exon 26 of the C4 gene. The C4A-isotypic residues PCPVLD modulate the reactivity of the thioester bond of the activated C4 molecule to bind to amino group-containing substrates, confer a relatively longer half-life against hydrolysis, and confer a higher affinity for complement receptor CR1. Therefore, it is thought that C4A is important in the solubilization of immune aggregates, immunoclearance, and opsonization. In contrast, the C4B-isotypic residues LSPVIH catalyze trans-esterification of the thioester carbonyl group of activated C4 to hydroxyl group-containing substrates preferentially, which is a very rapid but short-lived reaction (8 -10) . Hence, C4B is important for the propagation of the classical and the mannose-binding lectin (MBL) complement activation pathways, cumulating in the formation of the membrane attack complex against microbes (11) (12) (13) . The isotypic residues of C4A and C4B locate closely to another polymorphic region at positions 1188 and 1191, which determine the Rodgers (Rg) and Chido (Ch) blood group Ags. The close association of C4A to Rg Ags and C4B to Ch Ags helped the mapping of the C4 genes to the MHC (14) . The number of long or short C4A and C4B genes present in an individual plays a role in determining the basal level of C4 proteins in the peripheral blood plasma. Plasma C4 is chiefly secreted by the liver. Extrahepatic sites such as the kidneys, heart, adrenal glands, thyroid glands, pancreas, intestine, skin, synovial tissues, and CNS also synthesize C4 for local defense, by which the levels of C4 production are substantially increased upon IFN-␥ induction (2, 15, 16) .
Population studies revealed that deficiencies of C4A or C4B have a combined frequency of ϳ2% (5, 17, 18) . The presence of a single C4A or C4B gene in one or both MHC haplotypes and/or the isoexpression of C4A proteins only (or C4B proteins only) from bimodular and trimodular RCCX structures constitute complete or partial deficiencies of either C4A or C4B. Close to 30% of the normal population have relatively lower levels of either C4A or C4B proteins caused by the presence of only one C4A gene or only one C4B gene in a diploid genome (5, 19, 20) . Also, in HLA A2 Cw3 B60 DR6 haplotypes with bimodular LS structures for RCCX, the long C4A gene does not code for a protein product whereas the short C4B gene codes for C4B1 or C4B2 protein (21) . The mutant C4A gene, C4AQ0, is caused by frame-shift mutations due to a dinucleotide insertion in exon 29 at the sequence for codon 1213. This specific mutation has been detected in both healthy Caucasians and those with autoimmune disease (5, (21) (22) (23) (24) .
The great genetic diversity of human C4A and C4B genes leads to quantitative and qualitative variations of the polymorphic C4A and C4B proteins, which may be one of the intrinsic mechanisms in response to the selection pressure against a great variety of microbes or parasites. Deficiencies of C4A and/or C4B are associated with a variety of autoimmune or infectious diseases. For examples, deficiency of C4A or C4B is associated with type 1 diabetes (25) (26) (27) . Complete or partial deficiency of C4A is linked to systemic lupus erythematosus (SLE) (28 -31) , autoimmune hepatitis (32, 33) , and disease manifestation and rapid progression of AIDS in HIV-infected patients (34, 35) . Deficiency of C4B increases the vulnerability to bacterial (36, 37) and viral (38, 39) infections.
In contrast to the frequent partial or complete C4A or C4B deficiencies, complete deficiencies of both C4A and C4B in an individual is rare (23, 24, 40 -43) . Complete C4 deficiency is almost invariably discovered first in individuals or family members with SLE or other autoimmune disease (17) . Most complete C4-deficient patients regularly suffer recurrent bacterial or viral infections, are photosensitive, and have early onset lupus or lupus-like diseases (17) . Studying the clinical symptoms in C4-deficient patients may lead to better understanding of the physiological roles of human C4A and C4B. Investigating the molecular basis leading to complete C4A and C4B deficiencies will help in creating diagnostic techniques to detect C4 mutations. Here we report the clinical case history of a complete C4A-and C4B-deficient patient and the characterization of the molecular basis of different mutations in the C4AQ0 and C4BQ0 genes leading to frame-shift mutations and premature stop codons.
Materials and Methods

Genomic DNA, Southern blot analyses, and probes
Human genomic DNA was isolated from the peripheral blood or from B cell lines transformed with EBV strain NPC-LC of normal individuals, SLE patients and families, and from the cultured cell line MOLT4 (T cell leukemia) using the Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN).
Six micrograms of genomic DNA were digested to completion with the appropriate restriction enzyme, resolved on a 0.8% agarose gel, blotted onto Hybond-N ϩ membrane (Amersham Life Science, Arlington Heights, IL), and hybridized with appropriate [␣-
32 P]dCTP-labeled probe(s), as previously described (5, 44) .
Complement allotyping, assay of protein titers, and HLA typing
Complement C4A and C4B allotypes from EDTA-plasma samples were determined by immunofixation and immunoblot analyses as described previously (44 -46) . Ch and Rg phenotyping were performed on both RBC and plasma using standard serological methods. Complement C3 typing was performed by immunofixation of EDTA-plasma using a method similar to that of C4 except that the quantity of plasma was reduced by 5-fold. Goat antiserum for human C3 was purchased from Diasorin (Silverwater, MN).
C3 and C4 (C4A, C4B) levels were determined by radial immunodiffusion (47) , ELISA (48) , and total hemolytic complement in gels (Quantiplate; Kallestad, Beaumont, TX).
Typing of HLA-A, -B, and -DR Ags was performed by serology (49) at the University of Texas-Houston Medical School. HLA class II typings were by DNA oligotyping, as previously described (50) .
Synthetic DNA primers
Oligonucleotides of human C4 and RCCX constituents were designed based on published DNA sequences (51) (52) (53) 1, 3, 4, 5, 6, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31, 32, 33, 34, 35, 37, 38, 39, 40 , and 41. The primers were designed based on the genomic DNA sequence of C4A3a (51) .
Amplification of genomic DNA via PCR
A 2.4-kb fragment corresponding to the C4d region was amplified with synthetic PCR primers C4E22.5 and C4E31.3 using the Expand High Fidelity PCR system (Boehringer Mannheim, Indianapolis, IN). PCR conditions were: 1 cycle at 94°C for 2 min; 10 cycles at 94°C for 15 s, 65°C to 56°C for 30 s, and 72°C for 1 min; 20 cycles at 94°C for 15 s, 56°C for 30 s, and 72°C for 1 min plus time extensions of 20 s; and 1 cycle at 72°C for 7 min. Similarly, a 6.8-kb fragment spanning from C4 exon 1 to the C4B-isotypic site in exon 26 was amplified with synthetic PCR primers C4E1.5 and B-up, whereas a 7.0-kb fragment spanning from the isotypic site in exon 26 to C4 exon 41 was amplified with synthetic PCR primers B-down and C4E41.3. PCR conditions were: 1 cycle at 94°C for 2 min; 10 cycles at 94°C for 15 s, 64°C to 55°C for 30 s, and 68°C for 8 min; 20 cycles at 94°C for 15 s, 55°C for 30 s, and 68°C for 8 min plus 5-s time extensions; and 1 cycle at 72°C for 7 min.
Cloning and sequencing of C4d region and C4 exons 1-41
Genomic PCR products were purified (Qiagen, Chatsworth, CA) and cloned into the TA vector (Invitrogen, San Diego, CA). The presence of the correct size insert was verified via EcoRI restriction digests. Furthermore, to separate C4d clones into C4A and C4B isotypes, the C4d insert was amplified again via PCR, and the purified PCR product was restriction digested with NlaIV. A 467-bp fragment represents a C4B whereas two fragments (276 and 191 bp) represent C4A (19) . To verify that the amplified PCR products from the C4E1.5 to B-up and B-down to C4E41.3 reactions correspond to C4, the EcoRI-digested clones were subjected to Southern blotting and hybridized to a C4d-specific probe. Clones showing highlighted fragments corresponding to the correct size insert restriction fragments were considered positive.
DNA samples were sequenced on an automated system (ABI Prism, Foster City, CA). Comparison of DNA sequences with national databases was performed with the GCG FASTA program from the Pittsburgh Supercomputer Center (Pittsburgh, PA). DNA alignments were performed with the SeqManII program.
Sequence-specific PCR to detect C4 mutations
Detection of 2-bp insertion in C4 exon 29. The presence of a 2-bp insertion in C4A exon 29 (21) or C4B exon 29 (24) was detected via PCR using synthetic PCR primer pairs A-down and C4INS, and B-down and C4INS, respectively. PCR was performed with Taq DNA polymerase (Life Technologies). PCR conditions were: 1 cycle at 94°C for 5 min; 25 cycles at 94°C for 30 s, 65°C for 45 s, and 72°C for 1 min; and 1 cycle at 72°C for 10 min.
Detection of C4 exon 13 deletion via PCR. The existence of the 1-bp deletion in C4 exon 13 was confirmed via genomic PCR using synthetic PCR primers 13DELB and C4E14.3. PCR was performed with Taq DNA polymerase (Life Technologies). Conditions were: 1 cycle at 94°C for 5 min; 25 cycles at 94°C for 30 s, 65°C for 45 s, and 72°C for 1 min; and 1 cycle at 72°C for 10 min. Multiplex PCR. A multiplex PCR strategy was created to simultaneously report existence of all known C4 mutations in one DNA sample. Synthetic PCR primers 13DELB and C4E14.3 amplify a 400-bp fragment corresponding to the 1-bp deletion in exon 13; primers 29INSR and C4E26.5 amplify a 860-bp fragment corresponding to the 2-bp insertion in exon 29; positive control primers 21A5 and 21A3 amplify a 757-bp fragment corresponding to the gene CYP21. PCR was performed with Taq DNA polymerase, and conditions were: 1 cycle at 94°C for 5 min; 25 cycles at 94°C for 30 s, 60°C for 45 s, and 72°C for 1 min; and 1 cycle at 72°C for 10 min.
Results
Clinical case report
The proband was a 23-year-old white man born in 1978 who had recurrent viral and bacterial infections as a child, as well as fever, arthralgias, and rashes. In 1985, he was found to be totally deficient for C4. Between 1988 and 1989, fevers became higher and he developed dry eyes and dry mouth accompanied by a unilateral parotitis. Soon thereafter, he evolved a nondeforming polyarthritis, Raynaud's phenomenon, a photosensitive, maculopapular rash over the malar areas and arms, and multiple vasculitic lesions of the fingers and toes. An antinuclear Ab (ANA) assay was positive at 1:10,240, and other positive serologies included anti-Sm (Smith), anti-U1-ribonucleoprotein, and anti-cardiolipin Abs. Abs to dsDNA were consistently negative. He was diagnosed with SLE and Sjögren's syndrome and treated variously with prednisone, hydroxychloroquine, and cyclophosphamide. A renal biopsy in 1992 was read as WHO class III mild lupus nephritis. Since 1999, the proband declined further medication and did not consult a physician for Ͼ2 years. In October 2001, he was hospitalized after several months of increasing incoordination of gait, loss of fine motor control of arms and hands, slowed mentation, and somnolence. Magnetic resonance imaging of the brain showed multiple nonenhancing lesions throughout the cerebrum and cerebellum. Two brain biopsies were performed 1 month apart and showed multiple arterial walls infiltrated with mononuclear cells compatible with vasculitis. Cultures were negative. Despite high doses of corticosteroids (up to 1000 mg daily), the patient's neurological status continued to deteriorate, and he died.
The proband's parents and only sibling were examined in 1985 and 1988 and followed up by phone in 1998. The family had resided in Louisiana for several generations and was of French descent. Any consanguinity was denied. The deceased maternal grandfather had been diagnosed with discoid lupus. Both parents were healthy and had negative tests for ANA.
The proband's brother had developed biopsy-proved lupus rash of the face in 1981 at age 21 years, as well as recurrent oral ulcers and a transient polyarthritis. Residual rash of the face was present in 1988, but his examination was otherwise normal. Serum testing in 1988 showed negative tests for ANA, antidsDNA, anti-Ro (SS-A), anti-La (SS-B), anti-Sm (Smith), and anti-U1-ribonucleoprotein. Subsequently, he has remained healthy except for a persistent facial rash. He has not had an unusual frequency of infections. A diagram of the family pedigree is shown in Fig. 1A .
Phenotypic and genotypic analyses of C4 in the proband's family
EDTA-plasma samples from the proband (Fig. 1, lanes 1), his  brother (Fig. 1, lanes 2), and parents (Fig. 1, lanes 3 and 4) were used to show the polymorphism of complement C3 (Fig. 1B) and C4 (Fig. 1C) by immunofixation. Except for the patient's father who was homozygous for the slow-migrating variant of C3, C3S (Fig. 1B, lane 3) , the other three members of the family were all heterozygous for the fast-and slow-migrating variants of complement C3. Positive results of the C3 allotyping experiment suggested that the EDTA-plasma samples were not degraded.
No C4 proteins were detected in the samples of the proband and his brother, by both immunofixation (Fig. 1C) and immunoblot (Fig. 1D) analyses or by serological methods. A relative prominent band corresponding to C4A3 but not C4B was detected in the patient's father (Fig. 1C, lane 3) . As expected, this C4A3 allotype did not interact with the anti-Ch1 mAb (Fig. 1D, lane 3) . Both C4B1 and C4A3 protein were detectable in the mother (Fig. 1C,  lane 4) . The intensity of the C4B1 protein was considerably higher than that of C4A3. As shown in Fig. 1D , the C4B1 protein strongly reacted with the Ch1-monoclonal. Negative results for C4A and C4B proteins in the proband and his brother were obtained from blood samples obtained on multiple occasions using immunofixation, ELISA, and serological methods.
Genomic TaqI RFLP analysis of the family shows that the patient and his brother had homozygous, bimodular RCCX structures each with a long and a short C4 gene, i.e., LS/LS. In other words, four C4 genes present in each of their diploid genomes. The parents were heterozygous with two long C4 genes on one chromosome 6 (i.e., LL), and one long C4 gene and one short C4 gene on the other chromosome 6 (i.e., LS). In other words, the bimodular LS chromosomes were transmitted to the proband and his sibling. There were no unusual patterns for the neighboring genes RP, CYP21, and TNX.
Genomic PshAI RFLP experiments were performed to detect the quantitative variations of C4A and C4B genes (Fig. 1F) . Equal intensities of the 8.2-kb and 4.35-kb PshAI corresponding to C4B and C4A genes, respectively, were observed in the patient (Fig. 1F,  lane 1) , the sibling (Fig. 1F, lane 2) and their mother (Fig. 1F, lane  4) . Because each member of the family had four C4 genes, there are two C4A genes and two C4B genes in the proband, the sibling, and their mother. On the contrary, the band intensity of the C4A fragment was 3 times greater than that of the C4B fragment in the patient's father (Fig. 1F, lane 3) , suggesting the presence of three C4A genes and one C4B gene.
HLA typing of the class I and class II alleles revealed that the parents shared one common haplotype, A2 B12 and DR6 (DRB1*1302, DQA1*0102, DQB1*0604) (haplotype a), which were both transmitted to the proband and his sibling (Fig. 1, A and  G) . This haplotype has the LS structure for the bimodular RCCX and carries one nonexpressing C4A mutant gene (C4AQ0) and one nonexpressing C4B mutant gene (C4BQ0). Segregation analysis revealed that the other HLA haplotype (haplotype b) in the proband's father was A2 B16, C4A3 C4A3, and DR6 (DRB1*1302, DQA1*0102, DQB1*0604) in the class I, III, and II regions, respectively. The nontransmitted haplotype c in the mother was HLA A2 B12 C4A3 C4B1 DR6 (DRB1*1302, DQA1*0102, DQB1*0604). Haplotypes b and c both had the bimodular LL structure in the RCCX.
Mutation analyses at the C4d region via sequence-specific PCR and DNA sequencing
To determine whether the C4A and C4B mutant genes in the proband were the result of the TC/GA dinucleotide insertion into the sequence for codon 1213 in exon 29 of the C4A and C4B genes, sequence-specific PCR and DNA sequencing were performed. Genomic DNA from the patient's mother and father, the patient and his brother, positive controls F-M and F-F (24), and unrelated negative controls K1 and C1 were subjected to PCR using primers A-down and C4INS. The A-down primer selectively hybridizes to the C4A-isotypic site, and the C4INS primer anneals and primes DNA synthesis only to the sequence bearing the 2-bp insertion. The resulting 780-bp fragment represents the 2-bp insertion in C4A only. As shown in Fig. 2A , all members of the proband's family (Fig. 2, lanes 2-5) , exhibited the 780-bp fragment along with positive controls F-M and F-F (Fig. 2, lanes 6 and 7, respectively) , previously described as possessing the 2-bp insertion in C4A. No amplification product was observed in the unrelated negative controls K1 and C1 (Fig. 2, lanes 8 and 9, respectively) . To prove that the 780-bp fragment represents the exon 29 of C4, the gel was Southern blotted and hybridized to a C4 exon 29-specific probe. As shown in Fig. 2B , the probe hybridizes to the 780-bp fragment in lanes 2 through 7.
A similar PCR strategy was used to determine whether the C4B gene also contained the identical 2-bp insertion. Because the Bdown primer selectively binds to the isotypic C4B site, B-down and C4INS amplify this insertion only in C4B genes. No amplification products were observed in the proband's family members M, F, P, or B (data not shown).
To characterize the sequence polymorphisms of the C4 genes, the 2.4-kb genomic DNA fragments spanning from exon 22 to exon 31 corresponding to the patient's C4d was amplified via a high fidelity PCR, cloned into TA vector and sequenced (2) . The C4A and C4B clones were differentiated via a NlaIV digest (19) . The patient's C4d region of the C4B gene was sequenced to completion to verify the C4B nature of the clone. Accordingly, the clones contained the C4B-isotypic, derived amino acid sequence LSPVIH at positions 1101-1106, the C4B-associated amino acid sequence ADLR for the Ch1 Ag at positions 1188 -1191, S1157 that is associated with Ch6, and D1054 associated with Ch5 (54, 55) . However, congruent with results obtained by the PCR, the patient's C4B C4d region did not contain the 2-bp insertion in exon 29. A comparison of sequencing electropherograms at the exon 29 regions of both the patient's C4A and C4B is shown in Fig. 2C . The 2-bp insertion is evident in the electropherogram of the patient's C4A clone (Fig. 2C, left) , supporting the above described PCR results. This mutation was not observed in sequencing results from the patient's cloned C4d of the C4B gene (Fig. 2C, right) .
The recent publication of a 1-bp deletion (C) in sequence for codon 811 from exon 20 of C4A in another complete C4-deficient SLE patient (with HLA A30 B18 and DR3) (23) prompted us to investigate the presence of this mutation in the C4B of the patient, mother, and father. The region from intron 19 to exon 21 was amplified via PCR, cloned into TA vector, and sequenced. Again, the sequence for exon 20 was intact in each family member with no mutation found (data not shown).
Search for novel mutation in the proband's mutant C4B gene
To determine whether the molecular basis of the patient's C4B deficiency was the result of a novel mutation in the C4B coding sequence, a selective PCR strategy was designed to allow for sequencing of only the C4B gene. To selectively clone C4B, two PCRs were designed: one using synthetic primers C4E1.5 and B-up, which amplified exon 1 through the C4B-isotypic site of exon 26, and the other using primers B-down and C4E41.3, which amplified from the C4B-isotypic site of exon 26 to exon 41 (Fig.  3A) . The resulting PCR amplification products were purified, cloned into TA vector, and sequenced. To verify that the PCR products corresponded to C4, the EcoRI-digested clones were subjected to Southern blotting and hybridized to a C4d-specific probe (data not shown).
Several C4B clones were sequenced to completion. The size of the B-up clone, 6.8 kb, was indicative of the short C4B gene, which was missing the HERV-K(C4) retrovirus integration (6) . This PCR size confirms TaqI results, indicating that all of the patient's C4B genes are short. Similarly, the B-down clone contained C4B-specific amino acids ADLR for the Ch1-Ag at positions 1188 -1191, and S1157 associated with Ch6. Sequencing was completed with clones derived from two independent rounds of PCR amplification. Results from both rounds of PCR show the presence of a novel 1-bp deletion (C) at position 3671 in exon 13 of C4B, i.e., the sequence for codon 522 (Fig. 3C) . Sequence electropherograms derived from both forward and reverse primer positions are shown in Fig. 3B . Assuming correct splicing of the exon 13-intron 14 junction, this deletion resulted in a frameshift mutation and generated a premature stop codon (TGA) at aa 568 (Fig. 3D) .
A summary of the characteristic nucleotide and derived amino acid sequences (2) are shown in Table I . The CϾG767 mutation from exon 3 led to the L122V amino acid substitution that has not been reported in any other known C4 sequences. It has the AϾC2296 polymorphism from exon 9 that is responsible for the Y327S substitution, CϾT5056 from exon 17 that contributes to the L707P polymorphism, and a silent CϾT7308 mutation. Similar to the sequence for C4A3a, it has DNA sequence that codes for D1478.
Detection of mutations in C4 exon 13 and exon 29 in single multiplex PCR
A simple PCR strategy was devised to rapidly screen genomic DNA samples for the herein described C4 mutations in one reaction. As illustrated in Fig. 3A , PCR primers 13DELB and C4E14.3 amplify a 400-bp fragment corresponding to the 1-bp deletion in exon 13; primers 29INSR and C4E26.5 amplify a 860-bp fragment corresponding to the 2-bp insertion in exon 29; and positive control primers 21A5 and 21A3 amplify a 757-bp fragment corresponding to the gene CYP21. All three primers were added to the multiplex genomic DNA PCR. Fig. 3E shows that all members of the proband's family (Fig.  3E, lanes 1-4) possess both the 400-bp and 860-bp fragments, corresponding to the 1-bp deletion in exon 13 and the 2-bp insertion in exon 29, respectively. The F-M and F-F of family F possess only the 860-bp fragment corresponding to the exon 29 two-bp insertion. Negative controls Y1 and M1 do not have any C4 frameshift amplification products, suggesting intact C4A and C4B genes for these regions. However, the positive control band corresponding to 757-bp CYP21 is visible, confirming the presence of genomic DNA in the reaction.
Discussion
The tissues or organs (including the vasculatures, synovial tissues, kidneys, and CNS) afflicted with microbial infections or autoimmunity in the C4-deficient SLE patients were generally coincident with the locations where complement C4 would be present or expressed in normal individuals. This underscores the important roles of C4A and C4B: their complete absence substantially decreases the competence of systemic and local immune defense and immunoregulation.
Similar to our patient, complete C4-deficient patients may experience early onset SLE with fulminate and sometimes life-threatening infections (56, 57) . Besides the crippling effect of the broken link between the Ab-Ag (or MBL-Ag) interaction and the formation of the membrane attack complex, complete C4A and C4B deficiencies in humans impair the clearance of immune complexes by the erythrocytes, the phagocytosis of immune complex and apoptotic materials by macrophages, and the chemotaxis of inflammatory cells (58, 59) . It may also weaken adaptive immune response as a complete C4-deficient patient may have abnormal immunological memory and fail to switch from IgM to IgG during secondary response (56) . A similar phenomenon in the failure of secondary immune response had been observed in C4-deficient guinea pigs (60 -62). The redundancy of the immune defense system cannot be overlooked, however, because the male sibling of the SLE patient reported here with identical HLA haplotypes and complete C4A and C4B deficiencies experienced only mild lupus-like disease. In a previous case, a female Finnish SLE patient with complete C4 deficiency also had a male C4-deficient sibling who had only photosensitivity (Table  II; Ref. 24) . It is likely that in both of these cases the alternative and the MBL complement activation pathways were intact, and they fulfilled the effector arm of the humoral immune response. Under extreme situations with large quantities of Ag-Ab complexes and activated C1, the complement lytic pathway could be activated, bypassing C4, albeit inefficiently, using components of the alternative pathway (63, 64) . Moreover, these C4-deficient siblings might have protective genetic factors outside the MHC that render them less vulnerable to the full-blown disease. Alternatively, they might lack the additional genetic risk factor(s) for the diathesis of the complex disease, and/or they were not assaulted by the triggering environmental factors at a critical stage of development. The possible environmental factor could be a bad infection, hormonal stress, exposure to UV irradiation, or others (65) (66) (67) (68) .
The importance of genetic background for SLE disease manifestation has been clearly demonstrated in the mouse models with C4 knockout. Severe lupus symptoms were mainly observed in C4 knockout mice with CD95-deficient ( fas mutant) genetic background (69) , or in the C57BL6 -129 mixed genetic background (70) . Otherwise, the C4-null mice were relatively asymptomatic.
The HLA haplotype A2 Cw3 B40 (DR6) with monomodular long (mono-L) RCCX structure and a mutant C4A gene has been detected in six Caucasian patients from five independent families (17, 23, 24, 40 -43, 71) . This haplotype might have originated from the HLA A2 Cw3 B60 DR6 which has a mutant C4A gene and the short RCCX module with a C4B gene was lost through an unequal crossover. The 2-bp insertion might have spread to the C4A and C4B genes in other haplotypes including HLA A2 Cw7 B39 DR15 (24) and the C4A gene of the HLA A2 B12 DR6 described in this work. HLA A2, Cw3 and DR6 appear multiple times in patients with the identical defects in the C4AQ0 mutant genes. A different mutation leading to nonexpression of C4A by a 1-bp deletion at the sequence for codon 811 of exon 20 was observed in HLA A30 B18 DR3. In the current work, we discovered a novel mutation, i.e., 1-bp deletion in exon 13 at the sequence for codon 522, in a C4B gene that led to frame-shift mutation and premature termination. The patient is homozygous with this HLA haplotype with a long C4AQ0 gene and a short C4BQ0 gene. Another family with complete C4 deficiency also shared the same HLA A2 B12 haplotype, which might have the same molecular defects in the C4A and C4B genes (42) .
There are at least 11 additional HLA haplotypes with complete C4 deficiency. HLA A30 B18 DR7 is another common haplotype with complete C4 deficiency that has been detected in six individuals from three different families (41, 59, 72, 73) . By elucidating the sequence defects leading to the complete C4A and C4B deficiencies in these haplotypes, it may be possible to develop sequence-specific PCR technology, as illustrated in Fig. 3E , to detect the presence of mutant C4A and C4B genes. Such a technique would help epidemiological studies of diseases associated with complement C4A and C4B deficiencies. a Nucleotide numbering is referred to that of a short C4 gene, with the sequence for the A nucleotide of the initiation codon defined as nt 1 (2) . Derived amino acid sequences for C4BQ0 are hypothetical because there is no protein product. Unique sequence changes for C4BQ0 are in bold.
To date 28 complete C4-deficient individuals have been reported; all were typed for the HLA haplotypes, except the 3 subjects identified during a large scale medical survey of apparently healthy individuals (n ϭ 42,000) in Japan more than 30 years ago (23, 24, 40 -42, 56, 57, 59, 63, 71-80) . It is particularly striking that all HLA-typed, C4-deficient individuals but one (41) experienced symptoms related to immune complex or clearance disorders such as lupus or lupus-like disease, nephritis or kidney disease, and/or photosensitivity. Depending on the inclusion criteria, the disease penetrance of complete C4 deficiency ranges between 75 and 96%. Besides the genetic deficiency of complement C1q, there is probably no other known genetic deficiency that confers such a high penetrance of human systemic autoimmune disease as complete C4 deficiency (30, 81) .
